Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.
Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24:v1–95. https://doi.org/10.1093/neuonc/noac202.
Article CAS PubMed PubMed Central Google Scholar
Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381–97. https://doi.org/10.1016/b978-0-12-802997-8.00023-2.
Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406. https://doi.org/10.3322/caac.21693.
Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107:359–64. https://doi.org/10.1007/s11060-011-0749-4.
Article CAS PubMed Google Scholar
Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–401. https://doi.org/10.1126/science.1254257.
Article CAS PubMed PubMed Central Google Scholar
Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin Cancer Res. 2019;25:4202–10. https://doi.org/10.1158/1078-0432.ccr-18-1627.
Article CAS PubMed PubMed Central Google Scholar
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24:1459–68. https://doi.org/10.1038/s41591-018-0135-2.
Article CAS PubMed PubMed Central Google Scholar
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20:184–91. https://doi.org/10.1093/neuonc/nox175.
Article CAS PubMed Google Scholar
Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin’s disease after measles. Lancet. 1981;317:1112. https://doi.org/10.1016/s0140-6736(81)92286-8.
Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651–9. https://doi.org/10.1038/sj.mt.6300108.
Article CAS PubMed Google Scholar
Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16:2389–402. https://doi.org/10.1080/21645515.2020.1723363.
Article CAS PubMed PubMed Central Google Scholar
Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine. 2018;31:17–24. https://doi.org/10.1016/j.ebiom.2018.04.020.
Article PubMed PubMed Central Google Scholar
• Palanivelu L, Liu CH, Lin LT. Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy. Front Immunol. 2022;13:1038226. https://doi.org/10.3389/fimmu.2022.1038226. This is an informative review detailing the complex changes that oncolytic virotherapy can induce in the tumor microenvironment and the responding immune system. Understanding this interplay is critical for determining the optimal choice of virus and combinatorial strategy such as immune checkpoint inhibitors or CAR T/NK cells.
Article CAS PubMed Google Scholar
Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013;20:7–15. https://doi.org/10.1038/gt.2011.205.
Article CAS PubMed Google Scholar
Sooreshjani M, Tripathi S, Dussold C, Najem H, de Groot J, Lukas RV, et al. The use of targeted cytokines as cancer therapeutics in glioblastoma. Cancers (Basel). 2023;15:3739. https://doi.org/10.3390/cancers15143739.
Article CAS PubMed Google Scholar
Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari MJ, Zabibah RS, et al. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun Signal. 2023;21:43. https://doi.org/10.1186/s12964-022-01012-0.
Article PubMed PubMed Central Google Scholar
Hennessy C, McKernan DP. Anti-viral pattern recognition receptors as therapeutic targets. Cells. 2021;10:2258. https://doi.org/10.3390/cells10092258.
Article CAS PubMed PubMed Central Google Scholar
Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112. https://doi.org/10.1038/s41577-019-0215-7.
Article CAS PubMed Google Scholar
Sharma SK, Naidu G. The role of danger-associated molecular patterns (DAMPs) in trauma and infections. J Thorac Dis. 2016;8:1406–9. https://doi.org/10.21037/jtd.2016.05.22.
Article PubMed PubMed Central Google Scholar
Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79:191. https://doi.org/10.1007/s00018-022-04219-z.
Article CAS PubMed PubMed Central Google Scholar
Bencze D, Fekete T, Pázmándi K. Type I interferon production of plasmacytoid dendritic cells under control. Int J Mol Sci. 2021;22:4190. https://doi.org/10.3390/ijms22084190.
Article CAS PubMed PubMed Central Google Scholar
Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49. https://doi.org/10.1186/s40364-020-00228-x.
Article PubMed PubMed Central Google Scholar
Gillard AG, Shin DH, Hampton LA, Lopez-Rivas A, Parthasarathy A, Fueyo J, et al. Targeting innate immunity in glioma therapy. Int J Mol Sci. 2024;25:947. https://doi.org/10.3390/ijms25020947.
Article CAS PubMed PubMed Central Google Scholar
Koks CA, De Vleeschouwer S, Graf N, Van Gool SW. Immune suppression during oncolytic virotherapy for high-grade glioma; yes or no? J Cancer. 2015;6:203–17. https://doi.org/10.7150/jca.10640.
Article PubMed PubMed Central Google Scholar
Wang X, Shen Y, Wan X, Hu X, Cai WQ, Wu Z, et al. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy. J Transl Med. 2023;21:500. https://doi.org/10.1186/s12967-023-04360-8.
Article CAS PubMed PubMed Central Google Scholar
Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers (Basel). 2020;12:3219. https://doi.org/10.3390/cancers12113219.
留言 (0)